ClinicalTrials.gg
CompletedNCT01615328Updated Jul 23, 2014Results posted

Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™

A Phase 4 interventional study of Cervios ChronOs and Bonion in Intervertebral Disk Degeneration, Intervertebral Disk Displacement and Ossification of Posterior Longitudinal Ligament, sponsored by Seoul National University Hospital. Completed at 1 site in South Korea. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-07-23.

Sponsored by Seoul National University Hospital · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

Anterior cervical discectomy and fusion (ACDF) has shown good treatment results for a variety of cervical spine diseases such as herniated intervertebral disc (HIVD), cervical spondylotic radiculopathy (CSR) and cervical spondylotic myelopathy (CSM). ACDF using autogenous iliac bone graft is gold standard, however, it may lead to donor-site morbidities. Preventing these complications, some authors have tried to use alterative bone graft substitutes. Among these alternatives, Cervios ChronOs™ which is the polyetheretherketone (PEEK) cage with b-tricalcium phosphate (TCP) has become popular and shown good clinical results. However, b-TCP has only osteoconduction ability of three osteogenic properties.

Recently, Bonion™ which is the PEEK cage filled with hydroxyapatite (HA) / demineralized bone matrix (DBM) is introduced. HA/DBM mixture has abilities of osteoconduction and osteoinduction, therefore this alternative is expected to show superior bone fusion capability to PEEK cage with b-TCP. However, there has been no comparison study between the PEEK cage with b-TCP and the PEEK cage with HA/DBM. The purpose of this study is to evaluate bone fusion rate between these cervical spine cages using postoperative computed tomography (CT)

Read the detailed description

Biologically, graft material should be endowed with several basic properties. Several synthetic materials and graft substitutes have been developed to maximize fusion outcomes while avoiding complications of harvesting autograft. Mixture of hydroxyapatite (HA) and β-tricalcium phosphate (β-TCP), have been widely utilized for bony regeneration. On the other hand, demineralized bone matrix (DBM) has been utilized as a graft substitute with mainly its osteoinductive ability. While HA and β-TCP have osteoinductive osteoconductive properties and DBM has osteoconductive osteoinductive properties, a graft material fully incorporating both properties has not been developed. We hypothesize that an interbody graft material equipped simultaneously with osteoinductivity and osteoconductivity would enhance fusion achievement; however, clinical trials with mixture materials within a PEEK cage in ACDF surgery have rarely been performed.

02

Conditions studied

  • Intervertebral Disk Degeneration
  • Intervertebral Disk Displacement
  • Ossification of Posterior Longitudinal Ligament

Keywords

  • anterior cervical discectomy and fusion
  • bone graft substitute
  • PEEK cage
  • hydroxyapatite
  • demineralized bone matrix
  • b-tricalcium phosphate
  • Bonion
  • Cervios ChronOs
03

In context

Intervertebral Disc Degeneration

472 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

This study's enrollment of 85 is above the median of 60 across 268 interventional studies indexed under Intervertebral Disc Degeneration.

Browse Intervertebral Disc Degeneration studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,897 studies on the registry; 273 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of cervical HIVD, CSR, CSM or OPLL
  • The patient who is expected to receive anterior cervical discectomy and fusion operation.
  • Volunteer for this study with written consent.

Exclusion criteria

Exclusion Criteria:

  • Patient with cervical spine fracture, infection.
  • Below -3.5 T-score by DEXA bone densitometry
  • Patient with hemorrhagic diseases
  • Patient with malignancy
  • Patient who is not suitable for this study judged by principal investigator
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Cervios ChronOs

    The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.

    Device: Cervios ChronOs

  • Experimental
    Bonion

    The ACDF surgery will be carried out with Bonion(TM), which is the PEEK cage with HA/DBM.

    Device: Bonion

Interventions

  • DeviceCervios ChronOs

    The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.

  • DeviceBonion

    The ACDF surgery will be carried out with Bonion after randomization procedure.

06

What researchers measure

Primary outcomes

  1. Bone Fusion With CT(Postoperative 6 Months)

    Evaluation of bone fusion between bone substitutes and cervical vertebral endplates with 3-dimensional CT at 6 months after operation (ACDF).

    Time frame: 6 months after surgery(ACDF)

Secondary outcomes

  1. VAS of Radiating Pain (Postoperative 6 Months)

    Evaluation of radiating pain using the visual analogue scale (VAS) at 6 months after operation (ACDF). Reported pain using VAS was recorded and evaluated. Patients were instructed to make a mark on a horizontally-oriented, 10-point VAS labeled "no pain (zero point)" at the far left and "greatest pain (ten point)" at the far right.

    Time frame: at 6 months after surgery (ACDF)

  2. VAS of Neck Pain(Postoperative 6 Months)

    Evaluation of neck pain using the visual analogue scale (VAS) at 6 months after operation (ACDF). Reported pain using VAS was recorded and evaluated. Patients were instructed to make a mark on a horizontally-oriented, 10-point VAS labeled "no pain (zero point)" at the far left and "greatest pain (ten point)" at the far right.

    Time frame: at 6 months after surgery (ACDF)

07

Results

Posted Nov 18, 2013
Limitations and caveats
Our study was included relatively small samples and short follow-up periods with 77 patients and one year duration. the measurement bias could be presented by individually different extent of neck flexion and extension in dynamic radiographs.

Participant flow

Participant flow — Overall Study
MilestoneCervios ChronOSBonion
Started4243
Completed3938
Not completed35
Withdrew: Lost to follow-up35

Outcome measures

PrimaryBone Fusion With CT(Postoperative 6 Months)

Evaluation of bone fusion between bone substitutes and cervical vertebral endplates with 3-dimensional CT at 6 months after operation (ACDF).

Time frame:
6 months after surgery(ACDF)
Reported as:
Number · participants
Bone Fusion With CT(Postoperative 6 Months)
participantsCervios ChronOSBonion
Bone Fusion With CT(Postoperative 6 Months)2628
SecondaryVAS of Radiating Pain (Postoperative 6 Months)

Evaluation of radiating pain using the visual analogue scale (VAS) at 6 months after operation (ACDF). Reported pain using VAS was recorded and evaluated. Patients were instructed to make a mark on a horizontally-oriented, 10-point VAS labeled "no pain (zero point)" at the far left and "greatest pain (ten point)" at the far right.

Time frame:
at 6 months after surgery (ACDF)
Reported as:
Mean · scores on a scale
VAS of Radiating Pain (Postoperative 6 Months)
scores on a scaleCervios ChronOsBonion
VAS of Radiating Pain (Postoperative 6 Months)2.4 ± 2.32.9 ± 2.5
SecondaryVAS of Neck Pain(Postoperative 6 Months)

Evaluation of neck pain using the visual analogue scale (VAS) at 6 months after operation (ACDF). Reported pain using VAS was recorded and evaluated. Patients were instructed to make a mark on a horizontally-oriented, 10-point VAS labeled "no pain (zero point)" at the far left and "greatest pain (ten point)" at the far right.

Time frame:
at 6 months after surgery (ACDF)
Reported as:
Mean · scores on a scale
VAS of Neck Pain(Postoperative 6 Months)
scores on a scaleCervios ChronOsBonion
VAS of Neck Pain(Postoperative 6 Months)2.3 ± 2.42.0 ± 2.4

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cervios ChronOS—0/39 (0%)0/39 (0%)
Bonion—0/38 (0%)0/38 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cervios ChronOSBonionTotal
<=18 years000
Between 18 and 65 years333164
>=65 years6713
Age, Continuous
Age, Continuous(years)Cervios ChronOSBonionTotal
Mean51.3 ± 12.451.9 ± 11.751.6 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Cervios ChronOSBonionTotal
Female131326
Male262551
Region of Enrollment
Region of Enrollment(participants)Cervios ChronOSBonionTotal
Korea, Republic of393877
08

Study locations

1 site
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 463-707, South Korea
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2012
First posted
Jun 8, 2012
Start
Nov 2011
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Nov 18, 2013
Last update
Jul 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01615328
Responsible party
Jin S. Yeom (Associate Professor, Seoul National University Hospital) — Principal investigator
First posted
Jun 8, 2012
Start date
Nov 2011
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Nov 18, 2013
Last update
Jul 23, 2014

Study contacts

Jin Sup Yeom, MD, PhD
principal investigator · Seoul National Univerity Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion